Non-Hodgkin lymphoma: an update

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Non-Hodgkin lymphoma (NHL) incidence is rising globally, with largely unknown causes.
• Understanding of lymphocyte development and NHL pathogenesis has significantly advanced.
• NHL treatment options were limited to cytotoxic chemotherapy before the late 1990s.

Purpose of the Study:

• To review significant advancements in Non-Hodgkin lymphoma treatment over the past decade.
• To highlight the emergence and impact of novel therapeutic strategies.
• To provide an overview of current and developing treatment options for NHL.

Main Methods:

• Review of therapeutic strategies for Non-Hodgkin lymphoma.
• Analysis of treatment evolution from chemotherapy to targeted therapies.
• Inclusion of data on monoclonal antibodies and stem-cell reconstitution.

Main Results:

• High-dose chemotherapy with autologous stem-cell reconstitution is now standard for aggressive lymphoma.
• Monoclonal antibodies, such as Rituximab (anti-CD20), are established therapeutic options.
• Combination therapies (chemotherapy with monoclonal antibodies) and antibody-radionuclide conjugates show promise.

Conclusions:

• Significant progress has been made in NHL treatment over the last 10 years.
• Novel therapies, particularly monoclonal antibodies, have expanded treatment options and improved outcomes.
• Ongoing research continues to refine and develop new therapeutic approaches for NHL.